Abstract: Venous thromboembolism （VTE） is a prevalent complication among patients with malignant neoplasms，ranking as the second most common cause of mortality in this population surpassed only by tumor progression itself. Conventional thrombotic biomarkers exhibit notable limitations in assessing the hypercoagulable state associated with cancer and in diagnosing cancer-associated thrombosis （CAT），including suboptimal sensitivity and specificity，as well as ambiguous clinical interpretability of threshold values. These constraints may contribute to diagnostic delays or false-negative findings. In recent years，the identification and validation of novel thrombosis biomarkers have enabled a refined research framework and an integrated clinical management tool including dynamic risk stratification，early detection，intervention for prevention，and prognostic evaluation in thrombosis of cancer patients. This review synthesizes current evidence from both international and domestic studies to critically examine the evolving clinical utility of emerging thrombotic markers in the thrombosis management of cancer patients，and discusses their future potential，so as to provide a reference for clinical practice.